Servier invests Euro 40m in r&d site near Paris
The French family-owned group Servier plans to invest Euro 40m over four years to bolster its r&d site specialising in oncology and neurosciences at Croissy-sur-Seine, Yvelines, near Paris.
The French family-owned group Servier plans to invest Euro 40m over four years to bolster its r&d site specialising in oncology and neurosciences at Croissy-sur-Seine, Yvelines, near Paris.
This investment will see the r&d centre double in area, Servier said in a statement.
The extension will help strengthen the research capacity, particularly in biotechnology and therapeutic chemistry, added the French group, which ranks third in the world of independent pharma companies (behind German company Boehringer Ingelheim and US group Mundipharma).
"The first installation phase scheduled for the end of 2008 will involve three therapeutic chemistry units, a very high technology analytical chemistry unit and the whole of the scientific computing department," Servier said.
About 100 researchers will work in the new laboratories. They will be researchers collaborating with the Servier group, but there will also be a number of international post-doctorate or PhD students. Currently, the Servier research institute has 14 posts open for post-doctorates, the statement added.
The Croissy-sur-Seine site currently has about 200 employees. Some 20 posts were created in 2006 and 20 others will be created this year.
The group said that every year it invests almost a quarter of its turnover (which totalled €3.3 bn in 2006) in r&d.